| 1 |
|
DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective |
European journal of medicinal chemistry |
158 |
|
559-592 |
2018 |
Elsevier Masson |
| 2 |
|
Emergence of promising novel DPPâ4 inhibitory heterocycles as antiâdiabetic agents: A review |
Archiv der Pharmazie |
351 |
8 |
1800127 |
2018 |
|
| 3 |
|
Tubulin inhibitors as novel anticancer agents: an overview on patents (2013-2018) |
Expert opinion on therapeutic patents |
29 |
8 |
623-641 |
2019 |
Taylor & Francis |
| 4 |
|
Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review |
European journal of medicinal chemistry |
184 |
|
111773 |
2019 |
Elsevier Masson |
| 5 |
|
Synthetic lethality on drug discovery: an update on cancer therapy |
Expert Opinion on Drug Discovery |
15 |
7 |
823-832 |
2020 |
Taylor & Francis |
| 6 |
|
Aromatase inhibitors: Role in postmenopausal breast cancer |
Archiv Der Pharmazie |
353 |
8 |
2000081 |
2020 |
|
| 7 |
|
Free radical scavengers: An overview on heterocyclic advances and medicinal prospects |
European Journal of Medicinal Chemistry |
204 |
|
112607 |
2020 |
Elsevier Masson |
| 8 |
|
Design, in-silico study and biological evaluation of newly synthesized 3-chlorobenzofuran congeners as antitubercular agents |
Arabian Journal of Chemistry |
14 |
4 |
103034 |
2021 |
Elsevier |
| 9 |
|
Advances in 2âsubstituted benzothiazole scaffoldâbased chemotherapeutic agents |
Archiv der Pharmazie |
354 |
12 |
2100246 |
2021 |
|
| 10 |
|
Pharmacophore based drug design and synthesis of oxindole bearing hybrid as anticancer agents |
Bioorganic Chemistry |
116 |
|
105358 |
2021 |
Academic Press |
| 11 |
|
Synthetic approaches for oxazole derivatives: A review |
Synthetic Communications |
|
|
|
2021 |
Taylor and Francis |
| 12 |
|
Recent advances and SAR study of 2-substituted benzothiazole scaffold based potent chemotherapeutic agents |
Results in Chemistry |
4 |
|
100258 |
2022 |
Elsevier |
| 13 |
|
Advances of benzimidazole derivatives as anticancer agents: bench to bedside |
Benzimidazole |
|
|
|
2022 |
IntechOpen |
| 14 |
|
Novel approaches for the development of direct KRAS inhibitors: structural insights and drug design |
Expert Opinion on Drug Discovery |
17 |
3 |
247-257 |
2022 |
Taylor & Francis |
| 15 |
|
An appraisal of anticancer activity with structureâactivity relationship of quinazoline and quinazolinone analogues through EGFR and VEGFR inhibition: A review |
Drug Development Research |
83 |
4 |
859-890 |
2022 |
|
| 16 |
|
A comprehensive review on pyrazoline based heterocyclic hybrids as potent anticancer agents |
European Journal of Medicinal Chemistry Reports |
5 |
|
100042 |
2022 |
Elsevier Masson |
| 17 |
|
Design, synthesis, biological evaluation, and in silico studies of 2âaminobenzothiazole derivatives as potent PI3Kα inhibitors |
Archiv der Pharmazie |
355 |
10 |
2200146 |
2022 |
|
| 18 |
|
Synthesis, biological evaluation, and in silico studies of indoleâtethered pyrazoline derivatives as anticancer agents targeting topoisomerase IIα |
Drug Development Research |
83 |
7 |
1555-1577 |
2022 |
|
| 19 |
|
Strategies in synthetic design and structureâactivity relationship studies of novel heterocyclic scaffolds as aldose reductaseâ2 inhibitors |
Archiv der Pharmazie |
355 |
12 |
2200167 |
2022 |
|
| 20 |
|
Role of colchicine in the management of COVID-19 patients: A meta-analysis of cohort and randomized controlled trials |
Clinical Epidemiology and Global Health |
16 |
|
101097 |
2022 |
Elsevier |
| 21 |
|
Formulation and development of novel lipid-based combinatorial advanced nanoformulation for effective treatment of non-melanoma skin cancer |
International journal of pharmaceutics |
632 |
|
122580 |
2023 |
Elsevier |
| 22 |
|
Transferrin functionalized nanostructured lipid carriers for targeting Rivastigmine and Resveratrol to Alzheimer's disease: Synthesis, in vitro characterization and brain uptake analysis |
Journal of Drug Delivery Science and Technology |
86 |
|
104555 |
2023 |
Elsevier |
| 23 |
|
Author group and affiliations |
|
|
|
|
|
|
| 24 |
|
Results in Chemistry |
|
|
|
|
|
|
| 25 |
|
Development and Characterization of Oral Efavirenz-Loaded Nanostructured Lipid Carriers and Their Optimization with BoxâBehnken Design Approach for the Neurological Disorder |
ASSAY and Drug Development Technologies |
|
|
|
2025 |
Mary Ann Liebert, Inc., publishers 140 Huguenot Street, 3rd Floor New ⦠|
